These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31747714)

  • 1. Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma.
    Gibson M; Murrell DF
    Australas J Dermatol; 2020 May; 61(2):176-177. PubMed ID: 31747714
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
    Xie P; Lefrançois P
    J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
    Kutiel TS; Vornicova O; Bar-Sela G
    J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
    Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
    J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
    [No Abstract]   [Full Text] [Related]  

  • 11. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
    Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
    N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
    Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
    J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma.
    Jacobsen AA; Kydd AR; Strasswimmer J
    J Am Acad Dermatol; 2017 Apr; 76(4):767-768. PubMed ID: 28325399
    [No Abstract]   [Full Text] [Related]  

  • 18. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management.
    Le Moigne M; Saint-Jean M; Jirka A; Quéreux G; Peuvrel L; Brocard A; Gaultier A; Khammari A; Darmaun D; Dréno B
    Support Care Cancer; 2016 Apr; 24(4):1689-95. PubMed ID: 26416491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
    Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
    Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.